LPOXY Therapeutics, a pioneering biopharmaceutical corporation in the clinical development phase, is making notable strides in developing a preventive method for Clostridioides difficile infections that does not involve antibiotics. The company recently signed an agreement with 5Horizons Ventures, a recognized venture capital firm specializing in life sciences, with a proven track record of supporting revolutionary…
